Drug Profile
Bryostatin 1 - Synaptogenix
Alternative Names: Bryostatin-1 - Neurotrope; MW-904Latest Information Update: 21 Dec 2023
Price :
$50
*
At a glance
- Originator Blanchette Rockefeller Neurosciences Institute; Neurotrope BioScience
- Developer Blanchette Rockefeller Neurosciences Institute; National Cancer Institute (USA); National Institute on Aging; Rettsyndrome.org; Synaptogenix
- Class Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Behavioural disorder therapies; Macrocyclic compounds; Small molecules; Vascular disorder therapies
- Mechanism of Action Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Alzheimer's disease
- Preclinical Pervasive child development disorders
- No development reported Depressive disorders; Fragile X syndrome; Multiple sclerosis; Niemann-Pick disease type C; Parkinson's disease; Rett syndrome; Stroke; Traumatic brain injuries
Most Recent Events
- 19 Dec 2023 Updated efficacy data from a phase IIb trial in Alzheimer's disease released by Synaptogenix
- 26 Sep 2023 Efficacy data from phase II trial in Alzheimer's Disease released by Synaptogenix
- 28 Jul 2023 No recent reports of development identified for preclinical development in Depressive disorders in USA (IV)